Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADN-PAH: Pulmonary Artery Denervation for PAH
NCT02284737Phase 4Terminated
- Sponsor
- Nanjing First Hospital
- Start
- Nov 2014
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary arterial hypertension (PAH), sponsored by Nanjing First Hospital. Primary endpoint: Pulmonary arterial hypertension-related events at 6 months. Started Nov 2014; status: terminated.
02
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02284737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284737.